http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104698191-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2015-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104698191-B |
| titleOfInvention | SFTA3 application in lung squamous cancer and adenocarcinoma pathological diagnosis differentiate |
| abstract | The present invention relates to tetra-kinds of genes of CALML3, MLPH, TMC5, SFTA3 or the purposes of its detectable, for preparing the Differential Diagnosis reagent of lung squamous cancer and adenocarcinoma.The present invention is by carrying out statistical analysis to the mRNA sequencing result of lung squamous cancer and adenocarcinoma in TCGA data base, include 490 example lung squamous cancers and the data of 490 example adenocarcinomas of lung altogether in, find that CALML3, MLPH, TMC5, SFTA3 gene expression gap in lung squamous cancer and adenocarcinoma is very notable, be suitably applied the Differential Diagnosis of lung squamous cancer and adenocarcinoma.The method using SABC subsequently detects CALML3, MLPH, TMC5, SFTA3 gene expression in lung squamous cancer and adenocarcinoma tissue pathological section, it is determined that these genes differential expression in lung squamous cancer and adenocarcinoma and the using value in Differential Diagnosis. |
| priorityDate | 2015-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.